SAN DIEGO, Jan. 13, 2014 /PRNewswire/ --ResMed (NYSE: RMD) continues its 25-year history of innovating powerful and comfortable solutions for treating sleep-disordered breathing with today's introduction of the ultra-light, ultra-quiet ResMed AirFit' P10 nasal pillows system.
(Photo: http://photos.prnewswire.com/prnh/20140113/LA44444-a)
(Photo: http://photos.prnewswire.com/prnh/20140113/LA44444-b)
(Logo: http://photos.prnewswire.com/prnh/20100203/RESMEDLOGO)
The AirFit P10 weighs just 1.6 ounces, and has only three parts, including a new soft and stable QuickFit' headgear. ResMed has pioneered a new mesh vent called QuietAir' so the AirFit P10 is 50 percent quieter than its predecessor, diffusing air with minimal disturbance to patients or their bed partners. ResMed's AirFit P10 maintains a secure seal while delivering a high level of facial freedom.
"The AirFit P10's light weight and ultra-quiet performance also translates directly into better compliance," said Jon Yerbury, vice president of ResMed's Sleep-Disordered Breathing Strategic Business Unit. "Our internal research has shown that the AirFit P10 provides an average of 40 more minutes of sleep per night than ResMed's current market-leading nasal pillows mask."
For the convenience of ResMed's home medical equipment provider customers as well as patients, the AirFit P10 has color-coded cushion sizing, with small, medium and large sizes in the standard AirFit P10 system, and extra-small, small and medium sizes in the AirFit For Her system, which features headgear designed for women.
ResMed's AirFit P10 begins shipping in the U.S. today.
About ResMed:
ResMed is a global leader in the development, manufacturing and marketing of medical products for the diagnosis, treatment and management of respiratory disorders, with a focus on sleep-disordered breathing. The company is dedicated to developing innovative products to improve the lives of those who suffer from these conditions and to increasing awareness among patients and healthcare professionals of the potentially serious health consequences of untreated sleep-disordered breathing. For more information on ResMed, visit www.resmed.com.
Contacts: | |
For News Media | For Investors |
Gretchen Griswold | David Pendarvis |
Director, Global Corporate Communications | Chief Administrative Officer and Global |
O: 858-836-6789 | General Counsel |
news@resmed.com | O: 858-836-5983 |
David.Pendarvis@ResMed.com |
SOURCE ResMed Inc.
